Dr. Dennis Mulac

Mulac Dennis 3
© Dziemba

Lebensmittelchemiker

Institut für Pharmazeutische Technologie und Biopharmazie
der Westfälischen Wilhelms-Universität Münster
Corrensstr. 48
D - 48149 Münster

Raum C.110.157

Tel.: +49 (0)251 - 8339868
Fax: +49 (0)251 - 8339308
E-Mail: mulac.dennis AT uni-muenster DOT de

  • Preise

    PHOENIX Pharmazie Wissenschaftspreis 2016 - PHOENIX group
  • Projekte

    • BioTraP for CCC - Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N11390
  • Publikationen

    • Anderski J, Mahlert L, Sun J, Birnbaum W, Mulac D, Schreiber S, Herrmann F, Kuckling D, Langer K. . ‘Light-responsive nanoparticles based on new polycarbonates as innovative drug delivery systems for photosensitizers in PDT.’ International Journal of Pharmaceutics 557: 182-191.
    • Anderski J., Mahlert L., Mulac D., Langer K.Promising nanoparticulate drug delivery systems based on light-cleavable polymers.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Backhaus S., Mulac D., Langer K.Improved cellular uptake of different polysorbate 80-coated PLGA nanoparticles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Keuth J., Nitschke Y., Mulac D., Riehemann K., Rutsch F., Langer K.Reversion of arterial calcification by elastin targeted nanoparticles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Neufeld N., Mulac D., Langer K.Genipin crosslinked HSA nanoparticles for gene therapy: Impact of the crosslinker on transfection efficiency.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Partikel K., Mulac D., Langer K.The time-dependent nanoparticle-protein corona.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Stein N.C., Mulac D., Hermann F.C., Langer K.Preparation and characterization of protein-stabilized mTHPC nanosuspensions.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Wünsch A., Mulac D., Langer K.New lipid nanoparticle system based on lipoproteins: Cholesteryl oleate as solid core with different coatings.“ contributed to the NRW Nano-Conference, Dortmund, Deutschland, .
    • Alberding G., Mulac D., Langer K.PLGA nanoparticles for oral drug delivery: Know your basics to overcome the hurdles.“ contributed to the 8th NRW Nano-Conference, Dortmund, Deutschland, .
    • Franz J., Grünebaum J., Schäfer M., Mulac D., Rehfeldt F., Langer K., Kramer A., Riethmüller C. . ‘Rhombic organization of microvilli domains found in a cell model of the human intestine.’ PLoS ONE 13, Nr. 1. doi: 10.1371/journal.pone.0189970.
    • Wünsch A., Mulac D., Langer K.Formation of colloidal particles by dialysis of mixed albumin solution with lecithin emulsion: Incompatibility or chance for a new lipid-based drug delivery system? contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Raudszus B., Mulac D., Langer K. . ‘A new preparation strategy for surface modified PLA nanoparticles to enhance uptake by endothelial cells.’ International Journal of Pharmaceutics 536, Nr. 1: 211-221. doi: 10.1016/j.ijpharm.2017.11.047.
    • Gossmann R., Spek S., Langer K., Mulac D. . ‘Didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles: Uptake and cytotoxic potential in Caco-2 cells.’ Journal of Drug Delivery Science and Technology 43, Nr. null: 430-438. doi: 10.1016/j.jddst.2017.11.002.
    • Mahlert L., Anderski J., Mulac D., Langer K.Overcoming the mucus barrier - in vitro evaluation of mucus permeating nanoparticles for PDT.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Anderski J., Mahlert L., Mulac D., Sun J., Birnbaum W., Kuckling D., Langer K.Light-sensitive nanoparticles as innovative drug delivery systems for a controlled drug release.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Anderski J., Mahlert L., Mulac D., Langer K. . ‘Mucus-penetrating nanoparticles: Promising drug delivery systems for the photodynamic therapy of intestinal cancer.’ European Journal of Pharmaceutics and Biopharmaceutics 129: 1-9.
    • Sun J., Birnbaum W., Anderski J., Picker M.-T., Mulac D., Langer K., Kuckling D. . ‘Use of light-degradable aliphatic polycarbonate nanoparticles as drug carrier for photosensitizer.’ Biomacromolecules 19: 4677-4690.
    • Partikel K., Mulac D., Langer K.Compositional evolution of the nanoparticle-protein corona with increasing concentration of human serum.“ contributed to the 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Granada, Spanien, .
    • Stein N.C., Mulac D., Herrmann F.C., Langer K.Nanoparticle albumin-bound technology – Drug properties as a crucial aspect for an application.“ contributed to the DPhG Annual Meeting 2018, Hamburg, Deutschland, .
    • Mesken J., Iltsche A., Mulac D., Langer K. . ‘Modifying plasmid-loaded HSA-nanoparticles with cell penetrating peptides −cellular uptake and enhanced gene delivery.’ International Journal of Pharmaceutics 522: 198-209. doi: 10.1016/j.ijpharm.2017.03.006.
    • Lappe S., Mulac D., Langer K. . ‘Polymeric nanoparticles – Influence of the glass transition temperature on drug release.’ International Journal of Pharmaceutics 517, Nr. null: 338-347. doi: 10.1016/j.ijpharm.2016.12.025.
    • Partikel K., Korte R., Hoevelmann Y., Mulac D., Langer K.Effect of different serum types on the formation of the nanoparticle-protein corona.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Neufeld N., Mulac D., Langer K.Genipin as a bioalternative crosslinker for the stabilization of HSA nanoparticles. contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Backhaus S., Mulac D., Langer K.Different strategies for the formation of blood-brain barrier crossing PLGA nanoparticles.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Mesken J., Iltzsche A., Mulac D., Langer K. . ‘EB1 modified HSA nanoparticles as non-viral delivery vectors-Influence of peptide concentration on cell uptake.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.183.
    • Raudszus B., Partikel K., Mulac D., Langer K. . ‘Characterisation and cellular uptake of polysorbate 80-coated PLA nanoparticles.’ Contributed to the 7. NRW Nano-Konferenz, Münster, Germany. doi: 10.1016/j.matpr.2017.09.186.
    • Keuth J., Mulac D., Langer K.Challenges in development of EDTA-nanoparticles for therapy of calcification disorders.“ contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Anderski J., Mahlert L., Mulac D., Langer K.Photosensitizer-loaded nanoparticles: Promising drug delivery systems for photodynamic therapy of intestinal cancer? contributed to the DPhG Annual Meeting, Saarbrücken, Germany, .
    • Raudszus B., Partikel K., Mulac D., Langer K.Characterization and cellular uptake of polysorbate 80-coated PLA nanoparticles.“ contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Partikel K, Korte R, Mulac D, Langer K.Effect of nanoparticle size on the protein corona: A comparison between 100 and 200 nm PLGA nanoparticles. contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Anderski J., Mahlert L., Mulac D., Langer K.PLGA-based nanoparticles for oral application of photosensitizers as photodynamic therapy to treat gastrointestinal cancer. contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Niehoff A., Grünebaum J., Moosmann A., Mulac D., Söbbing J., Niehaus R., Buchholz R., Kröger S., Wiehe A., Wagner S., Sperling M., von Briesen H., Langer K., Karst U. . ‘Quantitative bioimaging of platinum group elements in tumor spheroids.’ Analytica Chimica Acta 938, Nr. null: 106-113. doi: 10.1016/j.aca.2016.07.021.
    • Mesken J, Mulac D, Langer K.Cell penetrating peptides as targeting ligands for nanoparticle based gene therapy – Influence on cellular uptake and transfection efficiency. contributed to the 7th NRW Nano-Conference, Münster, Germany, .
    • Mesken J., Mulac D., Langer K.Non-viral gene therapy: Successful uptake and transfection efficiency by plasmid-loaded protein-nanoparticles modified with cell penetrating peptides.“ contributed to the PBP World Meeting, Glasgow, UK, .
    • Grünebaum J., Söbbing J., Mulac D., Langer K. . ‘Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.’ International Journal of Pharmaceutics 496, Nr. 2: 942-952. doi: 10.1016/j.ijpharm.2015.10.023.
    • Gossmann R., Langer K., Mulac D. . ‘New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.’ PLoS ONE 10, Nr. 7. doi: 10.1371/journal.pone.0127532.
    • Gossmann R., Fahrländer E., Hummel M., Mulac D., Brockmeyer J., Langer K. . ‘Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.’ European Journal of Pharmaceutics and Biopharmaceutics 93, Nr. null: 80-87. doi: 10.1016/j.ejpb.2015.03.021.
    • Gossmann R., Hummel M., Mulac D., Brockmeyer J., Langer K.Cationic nanoparticles. An analytical approach to biological relevance.“ contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Gossmann R, Mulac D, Hummel M, Brockmeyer J, Langer K.Cationic nanoparticles as promsing drug delivery system? In detail characterization of surface properties.“ contributed to the DPhG Jahrestagung, Frankfurt, .
    • Wessels L, Tacke S, Mulac D, Langer K.Nanocapsules – Is the preparation of core-shell structured nanosystems that simple? contributed to the DPhG Jahrestagung, Frankfurt, .
    • Söbbing J, Grünebaum J, Mulac D, Langer K.Are polymeric nanoparticles able to cross the gastrointestinal barrier? contributed to the DPhG Jahrestagung, Frankfurt, .
    • Söbbing J, Mulac D, Wieland G, Wiehe A, Langer K.Preparation and physic-chemical evaluation of PLGA nanoparticles for photodynamic tumor therapy.“ contributed to the PBP World Meeting, Lissabon, .
    • Gonnisen D, Mulac D, Söbbing J, Grünebaum J, Fuchs H, Langer K, Riehemann K.Effects of PLGA nanoparticles on macrophages and cholangiocellular cancer cells. contributed to the Nanobio europe 2014, Münster, .
    • Niehoff A.-C., Moosmann A., Söbbing J., Wiehe A., Mulac D., Wehe C.A., Reifschneider O., Blaske F., Wagner S., Sperling M., von Briesen H., Langer K., Karst U. . ‘A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.’ Metallomics 6, Nr. 1: 77-81. doi: 10.1039/c3mt00223c.
    • Gossmann R, Mulac D, Langer K.New perspective in the formulation and characterization of DMAB-stabilized PLGA nanoparticles.“ contributed to the PBP World Meeting, Lissabon, .
    • Mulac D, Fahrländer E, Gossmann R, Langer K.Comparative examination of adsorption of serum proteins on HSA and PLGA based nanoparticles.“ contributed to the PBP World Meeting, Lissabon, .
    • Engel A., Ploger M., Mulac D., Langer K. . ‘Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.’ International Journal of Pharmaceutics 461, Nr. 1: 137-144. doi: 10.1016/j.ijpharm.2013.11.044.
    • Grünebaum J, Söbbing J, Mulac D, Langer K.Improved photocytotoxicity in cholangiocellular cell lines with mTHPP-loaded PLGA nanoparticles. contributed to the PBP World Meeting, Lissabon, .
    • Mulac D, Lepski S, Ebert F, Schwerdtle T, Humpf HU. . ‘Cytotoxicity and fluorescence visualization of ergot alkaloids in human cell lines.Journal of agricultural and food chemistry 61, Nr. 2: 462-71. doi: 10.1021/jf304569q.
    • Söbbing J, Grünebaum J, Mulac D, Langer K.Preparation and biological evaluation of mTHPP-loaded PLGA nanoparticles for photodynamic tumor therapy.“ contributed to the DPhG Jahrestagung, Freiburg, .
    • Grünebaum J, Söbbing J, Engel A, Mulac D, Langer K.Methodische Voraussetzung zur Untersuchung der Permeabilität von Nanopartikeln am Caco-2 Modell.“ präsentiert auf der Transportertage Bad Herrenalb, Bad Herrenalb, .
    • Mulac D, Hüwel S, Galla HJ, Humpf HU. . ‘Permeability of ergot alkaloids across the blood-brain barrier in vitro and influence on the barrier integrity.Molecular nutrition & food research 56, Nr. 3: 475-85. doi: 10.1002/mnfr.201100431.
    • Mulac D, Grote AK, Kleigrewe K, Humpf HU. . ‘Investigation of the metabolism of ergot alkaloids in cell culture by fourier transformation mass spectrometry.Journal of agricultural and food chemistry 59, Nr. 14: 7798-807. doi: 10.1021/jf2012024.
    • Mulac D, Grote AK, Kleigrewe K, Humpf HU.Uptake and Metabolism of Ergot Alkaloids in Human Cells.“ contributed to the Mykotoxinworkshop, Freising, .
    • Mulac D., Königs M., Schwerdt G., Gekle M., Humpf H. . ‘Safety Assessment of Botanicals and Botanical Preparations Used as Ingredients in Food Supplements: Testing an European Food Safety Authority-Tiered ApproachRisk Assessment of T-2 and HT-2 Toxin Using Human Cells in Primary Culture.’ In Risk Assessment of Phytochemicals in Food: Novel Approaches, edited by Wiley-Blackwell, 420. Wiley-Blackwell. doi: 10.1002/9783527634705.ch4.
    • Mulac D, Hüwel S, Galla HJ, Humpf HU.Einfluss von Mutterkornalkaloiden auf die Blut-Hirn-Schranke im in vitro Modellsystem.“ präsentiert auf der Treffen der Blut-Hirn-Schranke Experten und Caco-2 Anwender, Bad Herrenalb, .
    • Mulac D, Königs M, Schwerdt G, Gekle M, Humpf HU.Risk assessmentof T-2 and HT-2 toxin using human cells in primary culture.“ contributed to the SKLM, Kaiserslautern, .
    • Mulac D, Humpf HU.Cytotoxic effects of ergot alkaloids on human primary cells.“ contributed to the Single Cell and Molecule Analysis, Münster, .
    • Fraske A, Harrer H, Hübner F, Königs M, Mulac, D, Humpf, HU.Large-scale Isolation and Purification of Fumonisins using Fast Centrifugal Partition Chromatography (FCPC).“ contributed to the Mykotoxinworkshop, Utrecht, .
  • Vorträge

    • Anderski, Juliane; Mahlert, Laura (): ‘Interactions of nanoparticles with mucus - the first barrier before reaching intestinal cells’. Bad Herrenalber Transporter- und Barrieretage, Bad Herrenalb, Deutschland, .
    • Raudszus, Bastian; Mulac, Dennis; Langer, Klaus (): ‘Apo E-modification of PLA-nanoparticles enhances cellular uptake into brain endothelium’. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, Vereinigtes Königreich, .

Praktikumsbetreuung:

  • Praktikum: "Pharmazeutische Technologie einschl. Medizinprodukte" :
    • Feste Arzneiformen
    • Sterile Arzneiformen